9 5 3 6 3
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.3 Breast Cancer (Dove Med Press)
- 3.4 Clin Epidemiol
- 2.5 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.5 Clin Interv Aging
- 4.7 Drug Des Dev Ther
- 2.7 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.5 Int J Women's Health
- 2.5 Neuropsych Dis Treat
- 2.7 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.3 Ther Clin Risk Manag
- 2.5 J Pain Res
- 2.8 Diabet Metab Synd Ob
- 2.8 Psychol Res Behav Ma
- 3.0 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.7 Risk Manag Healthc Policy
- 4.2 J Inflamm Res
- 2.1 Int J Gen Med
- 4.2 J Hepatocell Carcinoma
- 3.7 J Asthma Allergy
- 1.9 Clin Cosmet Investig Dermatol
- 2.7 J Multidiscip Healthc
病例报道：一例 EGFR 基因突变的肺癌患者及其耐药机制探讨
Authors Xu L, Wang QZ, Wu L
Received 8 June 2017
Accepted for publication 11 August 2017
Published 12 September 2017 Volume 2017:10 Pages 4517—4525
DOI https://doi.org/10.2147/OTT.S143501
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Akshita Wason
Peer reviewer comments 5
Editor who approved publication: Dr Samir Farghaly
摘要：在过去的十年中，随着针对特殊基因改变的靶向治疗的发展，如 EGFR 等，肺癌的治疗发生了翻天覆地的变化，取得了极大的进步。在这里，我们报道一个罕见病例，该患者初始基因检测含有 EGFR 敏感突变及 ALK 过表达。在 EGFR-TKI 治疗期间 ，二代测序技术先后在肿瘤标本中发现 PI3K/AKT/mTOR 途径激活，在血浆 ctDNA 中检测出 T790M 突变。总之，该病例体现了双重耐药机制的存在以及 ctDNA 能检测出肿瘤异质性。
Keywords: epidermal growth factor receptor,
PI3K/Akt/mTOR pathway, T790M, next-generation sequencing, circulating tumor DNA
